Clinical Cardiology Research and Reports

www.alcrut.com

Research Article | Clinical Cardiology Research and Reports | Open Access

The Role of Periostin in Elastin Mediated RASMC Calcification In Vitro And Medial Calcification In Vivo In a Rat Model

Yogesh Chowdary
Department of Cardiology, Hospital Universitari de Bellvitge, Barcelona, Spain

***Corresponding Author**: Yogesh Chowdary, Department of Cardiology, Hospital Universitari de Bellvitge, Barcelona, Spain

Received Date: March 22, 2022; **Accepted Date:** April 05, 2022; **Published Date:** April 08, 2022

Citation: Yogesh Chowdary, The Role of Periostin in Elastin Mediated RASMC Calcification In Vitro And Medial Calcification In Vivo In a Rat Model, J Clinical Cardiology Research and Reports

Abstract

Vascular calcification is a point of both advanced atherosclerosis and medium roadway calcification also known as Monckeberg's sclerosis. medium arterial calcification (MAC) is the mineral deposit in the media of highways and is generally associated with elastin. It occurs singly of atherosclerotic shrine. MAC is observed with particularly high frequence in diseases like end- stage renal complaint and diabetes mellitus and it's known to increase mortality and amputation pitfalls. Both diabetes and habitual order complaint have been honored aspro-inflammatory conditions and they increase expression of excrescence necrosis factor- nascence (TNF- α) in highways which haspro-osteogenic parcels Inflammation in highways is known to increase matrix demeaning enzymes similar as matrix metalloproteinases (MMPs) and cathepsins.

Keywords: Arteriosclerosis; medial arterial calcification; smooth muscle cells; osteogenesis; calcific disease; elastocalcinosis

Introduction

Vascular calcification is a point of both advanced atherosclerosis and medium roadway calcification also known as Monckeberg's sclerosis (1). medium arterial calcification (MAC) is the mineral deposit in the media of highways and is generally associated with elastin. It occurs singly of atherosclerotic shrine (2). MAC is observed with particularly high frequence in diseases like end- stage renal complaint and diabetes mellitus and it's known to increase mortality and amputation pitfalls (3- 4). Both diabetes and habitual order complaint have been honored aspro-inflammatory conditions and they increase expression of excrescence necrosis factor- nascence (TNF- α) in highways which haspro-osteogenic parcels (5). Inflammation in highways is known to increase matrix demeaning enzymes similar as matrix metalloproteinases (MMPs) and cathepsins (6- 8), which can break down elastic filaments in the media. In diabetic conditions, elevated situations of elastin deduced peptides are set up in serum (9- 11). It's known that the smooth muscle cells suffer morphological changes to osteoblast- suchlike cells in MAC (12). We've shown before that MMPs play a significant part in elastin declination and calcification (13). Rat aortic smooth muscle cells (RASMCs) have shown to increase osteogenic genes with the exposure of elastin fractions along with transubstantiating growth factor, (TGF- β1) (14). still, how elastin peptides and TGF- β1 triggers this metamorphosis of RASMCs has not been completely delved. Understanding the part of motes that regulate the process of elastin intermediated vascular calcification is the focus of our study.

Osteoblast-specific factor 2 (OSF2), also appertained to as periostin, was first linked using subtractive hybridization ways on MC3T3- E1 osteoblast- suchlike cells and was allowed

at that time to be bone-specific (15). Firstly nominated osteoblast specific factor- 2 (OSF- 2); it was renamed periostin due to localized expression in the periosteum and the periodontal ligament (16). Periostin (postn) expression has been intertwined in heart stopcock morphogenesis (17) and in osteogenesis (18). Periostin isn't detected in adult apkins except under conditions of habitual load, injury, stress, or pathology. Norris etal., were the first to propose that periostin should be classified as a matricellular protein due to its capability to interact with matrix factors to serve a structural part and its capability to interact with cell face receptors and regulate signaling processes (19).

We wanted to test if periostin is the foremost marker in the osteogenic process in RASMCs. Then we show that RASMCs after exposure to elastin fractions and TGF- β1 express high situations of periostin before calcification and blocking of relations of RASMCs with elastin and TGF- β1 reduce the situations back to the normal cells. also, inhibition of periostin blocked RASMC calcification, whereas overexpression promoted calcification.

styles

Cell culture and treatments

Primary rat aortic smooth muscle cells and cell line (Cell Applications Inc, San Diego, CA, USA) from passage 5- 8 were used in all trials. Cells(n = 6 wells/ group, 6 × 105/ well) were treated with answerable elastin peptide, purified from bovine neck ligament and contained the specific repeating peptide sequence VGVAPG(CB 573, Elastin Products Company, Owensville, MO), recombinant mortal TGF- β1(PeproTech,Inc., Rocky Hill, NJ, USA), lactose and SB431542(Sigma,St. Louis, MO, USA) as follows 100 μg/ ml elastin peptide(elastin group); 10 ng/ ml TGF- β1(TGF group); 100 μg/ ml elastin peptide and 10 ng/ ml TGF- β1(elastin TGF group); 100 μg/ ml elastin peptides and 5 mmol/ L lactose(elastin lactose group); 10 ng/ ml TGF- β1 and 10μm SB431542(TGF SB43 group), and medium alone(control group). Culture media were replaced every 3 days with fresh Dulbecco's modified Eagle's medium supplemented with the applicable agents in attention described over. Gene and protein expression from cell excerpts were anatomized after 3 days to 4 weeks as described below. Calcium deposit was estimated by von Kossa staining of cells maintained in culture for over to 21 days.

Rat aortic calcification model Adult manly Sprague- Dawley rats importing 250- 300g were placed under general anesthesia (2- 3 isoflurane) and the infrarenal abdominal aorta were treated periadventitially for 15 twinkles with0.15 spook/ L CaCl2 or0.15 spook/ L NaCl as controls (n = 6 rats per group) using the reek

operation system described preliminarily (15).

The disquisition conforms with the companion for the Care and Use of Laboratory creatures published by the US National Institutes of Health (NIH PublicationNo. 85- 23, revised 1996). The beast protocols were approved by the Clemson University Animal Research Committee (AUP2011052).

RT- PCR for gene analyses

Total RNA was insulated from cells using the RNeasy Mini tackle (Qiagen, Valencia, CA). For gene expression, Gene expression in each sample was regularized to the expression of a housekeeping gene (GAPDH) and compared with control samples using the 2 − ΔΔCT system (21).

Immunofluorescence and western blotting for periostin

Standard protocols were used to descry periostin by immunofluorescence and western blotting with rabbitanti-periostin antibody. Details can be set up in an online supplement.

Von kossa staining for calcification

Cells in 3 weeks culture were incubated with 1 tableware nitrate result and placed under UV light for 20 twinkles. After several changes of distilled water, the unreacted tableware was removed with 5 sodium thiosulfate for 5 twinkles, and the cells were irrigated and kept in distilled water. The presence of black stain verified the presence of calcium phosphate deposits.

Adenoviral and lentiviral construction

Adenoviral construction was performed as preliminarily described by us (22). Details can be set up in on- line supplement. Selfinactivating replication unskillful viral patches were produced in packaging cells (HEK293T) byco-transfection with compatible packaging plasmids as preliminarily described (23). The p24 titering assay was employed to determine shRNA lentiviral titers of 106 TU/ ml. A aggregate of 5 shRNA lentiviruses were generated and tested for functionally blocking periostin expression.

Adenoviral and lentiviral shRNA transduction for RASMC

RASMCs at 50 convergences were infected with mouse periostinover-expressing adenovirus (PN OX) or periostin knockdown shRNA lentivirus (PN AS) at a attention of 300 and,000 contagion flyspeck per cell independently in serum-free media. One day previous to contagion infection, cells were treated with elastin peptide and TGF- β1. Media were replenished every 3 days with fresh test agents. Cells were gathered at 3 and 7 days for RNA and protein birth independently. Whole cell lysates were used for western spot to determine protein situations of periostin.

Statistical analysis

Results are expressed as means ± SEM. Statistical analyses of the data were performed using single- factor analysis of friction. Statistical differences were determined using the pupil t- test with an α value of0.05.

Results

To study if periostin expression is linked to medium calcification, we examined the effect of elastin peptides and TGF- β1 on the regulation of periostin expression in smooth muscle cells, a major cell population present in tunica media of arterial wall. We've preliminarily shown that exposure of elastin peptides with TGF- β1 to vascular smooth muscle cells leads to osteogenic phenotype (14).

Discussion

We delved the effect of elastin declination products and TGF- β1 on the expression of postn in the smooth muscle cell line and in primary cells. We chose to combine TGF- β1 with elastin peptides as TGF- β1 is known to be sequestered in elastic filaments and declination of elastic fiber would release active TGF- β1 in the roadway. former report from our laboratory have shown that in response to elastin peptides and TGF- β1, rat aortic smooth muscle cells separate into cells that parade an osteoblast- suchlike phenotype, characterized by the expression of genes typically confined to mineralized towel, including Cbfa- 1, osteocalcin and alkaline phosphatase (14).

We set up a remarkably strong expression of periostin when cells were exposed to combination of elastin peptide plus TGF- β1 as substantiated by RT- PCR, western spot, and immuno- luminescence. Time course studies revealed that the expression position of periostin mRNA transiently increased by 1 week, remained constant at week 2 and returned to the rudimentary position by 4 weeks. still the full length, 90 KD postn protein was expressed only at 1wk. The lack of expression of periostin protein at 2 and 4 wks in the smooth muscle cells support the thesis that the cells at these time points represent a important after stage of isolation, while strong expression of periostin at 1 wk suggests that the cells at this early time point retainpre-osteoblast like parcels. Horiuchi etal., (24) have shown that periostin is a specific marker for preosteoblasts. They showed that postn is a disulfide linked 90kd a protein buried by osteoblasts and osteoblast like cell lines. During farther isolation of these cells into mature osteocytes, a decline in the expression of periostin is sensible and osteocytes no longer synthesize this protein (25). This was also demonstrated in a study of different cell lines in which the preosteoblast to osteocyte ontogeny was shown grounded on the expression of bone-specific labels. The results indicated that the murine calvarial osteoblast cell line MC3T3- E1 expresses periostin and thus these cells were interpreted as preosteoblasts. In MLO- A5, MLO- C2, MLO- D1, MLO- D6 and MLO- Y4 cells the product of periostin was lowered and therefore these cells were considered at a after stage of isolation analogous to osteocytes (27). In harmonious with these studies, our data thus suggest that periostin expression is confined only at early stages of RASMC isolation.

The high postn expression was effectively inhibited by lactose, an elastin laminin receptor (ELR) antagonist and by SB431542, a TGF- β1 receptor antagonist. Elastin peptides are known to interact with cells through ELR. Lactose is a picky elastin laminin receptor (ELR) antagonist (28). SB431542 is a potent and largely picky small- patch asset of TGF- β1-dependent signaling (29). therefore, the present study demonstrated that elastin peptide or TGF- β1 intermediated stimulation of postn mRNA expression in SMCs in vitro is receptor dependent and is intermediated by TGF- β R1 and ELR. This effect was further verified when cells were concomitantly treated with elastin peptide, lactose and TGF- β1 to block the function of ELR. As anticipated, postn expression was restored back to that position observed in TGF- β1 treatment alone indicating that both ELR and TGF- β R1 are involved in this upregulation. further work is demanded to find out how the crosstalk between these two transduction pathways takes place to increase periostin gene expression.

To test if periostin is one of the foremost labels in osteogenesis, RASMC cells exposed to elastin peptides and TGF- β were treated with lentiviral shRNA to knockdown the expression of periostin. The use of viral vectors to inhibit protein exertion, is an accepted fashion, used successfully by others (22). We tested the expression of osteoblast-specific labels, similar as alkaline phosphatase (peak), Cbfa- 1 and osteocalcin, to give sapience into the part of periostin in osteogenesis. Cbfa- 1 and peak were markedly reduced by shRNA treatment. Cbfa- 1 expression in RASMCs serves as an early, definitive marker of osteoblastic isolation, the original step in vascular calcification. Cbfa- 1 is a recap factor that controls the expression of a number of proteins associated with osteoblastic isolation, including osteocalcin, OPN, and type I collagen (30). peak is a functional, phenotypic marker of osteoblasts, and peak exertion is frequently used as a molecular marker for vascular calcification, as it's an early index of mineral matrix deposit (31). peak exertion is pivotal to hydroxyapatite conformation during endochondral ossification (32). In medium calcification, SMCs express advanced situations of peak (33). Alkaline phosphatase modulates vascular calcification by dwindling situations of inorganic pyrophosphate, which is a substrate for peak and an honored potent asset of vascular calcification (35). As both Cbfa- 1 and peak expression was down regulated by shRNA intermediated downregulation of postn in RASMCs, postn may be an upstream of peak and Cbfa- 1. Osteocalcin is a marker of latestage osteoblast isolation, and the lack of this gene reportedly causes an increase in bone conformation in mice (36). Interestingly in the present study, we set up that the stimulatory effect of elastin peptides on the expression of osteocalcin wasn't reduced in postn knockdown cells, suggesting that postn knockdown effect is more specific, inhibiting only the early labels of isolation and not the late labels similar as osteocalcin. Reduction in the expression of bone specific labels in cells with reduced (knocked down) expression of postn also led to dropped RASMC calcification at a after stage. RASMC cells began to form nodes at 7 days after elastin peptide and TGF- β1treatment; the multilayered cells also came polygonal in shape and formed nodes. Von Kossa staining showed that the maturity of the nodes were darkly stained in RASMC cells at 21 days after the elastin peptide and TGF- β1 treatment. still, significantly lower mineralization was observed in postn knockdown lentivirus treated cells indicating periostin reduction inhibit calcification and suppress the induction of osteoblast like phenotype in smooth muscle cells. Not only knockdown of postn reduced calcification, but we also set up that overexpression of postn with transduction of adenovirus garbling postn was sufficient to induce calcification of RASMCs. This is harmonious with a former study showing that adenoviral gene transfer of periostin like factor (PLF) an isoform related to postn enhanced the osteogenic isolation and mineralization of primary osteoblast cells (37). Our results explosively indicate that postn plays an essential part in elastin intermediated RASMC calcification in vitro, and postn overexpression alone is sufficient to induce RASMC calcification in absence of elastin peptides

and TGF- β1.

Encouraged by the robust induction of postn in RASMC cell culture studies, we were interested in studying the regulation of postn in circulatory beast model where medium vascular calcification is observed. former studies from our laboratory have shown that CaCl2 intermediated aortic injury leads to elastin specific medium calcification in the abdominal aorta of rats (13). In the present study we saw a several fold inductions of periostin at gene and protein at 3 and 7 days after injury along with medium calcification as compared to NaCl treated control group, which didn't lead to elastin calcification. We've observed advanced elastin declination and increased TGF- β1 situations in the calcified regions of the roadway in this beast model of vascular calcification. Therefore our cell culture results were corroborated in a circulatory model showing that postn expression is the critical early event in early stage medium calcification.

Summary

The present study provides the first substantiation of the part of Postn in elastin intermediated RASMC calcification in vitro and medium calcification in vivo in a rat model. We also demonstrated that calcification in RASMC proceeds through osteogenic isolation with the induction of postn that alters the expression of downstream bone specific proteins that lead to calcification. still, more in vivo clinical data is demanded to further probe the part of postn in vascular calcification.

Competing interests

The authors declare that they have no competing interests.

References

1. Trion A and van der Laarse A: **Vascular smooth muscle cells and alcification in atherosclerosis**. *Am Heart J* 2004, **147**:808-14.
2. Proudfoot D and Shanahan CM: **Biology of calcification in vascular cells: intima versus media**. *Herz* 2001, **26**:245-51.
3. Amann K: **Media calcification and intima calcification are distinct entities in chronic kidney disease**. *Clin J Am Soc Nephrol* 2008, **3**:1599-605.
4. Soor GS, Vukin I, Leong SW, Oreopoulos G and Butany J: **Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases**. *Pathology* 2008, **40**:385-91.
5. Al-Aly Z: **Medial vascular calcification in diabetes mellitus and chronic kidney disease: the role of inflammation**. *Cardiovasc Hematol Disord Drug Targets* 2007, **7**:1-6.
6. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E and Libby P: **Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions**. *Ann N Y Acad Sci* 1995, **748**:501-7.
7. Chung AW, Yang HH, Sigrist MK, Brin G, Chum E, Gourlay WA and Levin A: **Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease**. *Cardiovasc Res* 2009, **84**:494-504.
8. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG and Tsao PS: **Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress**. *Circ Res* 2001, **88**:1291-8.
9. Bizbiz L, Alperovitch A and Robert L: **Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study**. *Atherosclerosis* 1997, **131**:73-8.
10. Fulop T, Jr., Wei SM, Robert L and Jacob MP: **Determination of elastin peptides in normal and arteriosclerotic human sera by ELISA**. *Clin Physiol Biochem* 1990, **8**:273-82.
11. Nicoloff G, Petrova C, Christova P and Nikolov A: **Detection of free elastin-derived peptides among diabetic children**. *Atherosclerosis* 2007, **192**:342-7.
12. Johnson RC, Leopold JA and Loscalzo J: **Vascular calcification: pathobiological mechanisms and clinical implications**. *Circ Res* 2006, **99**:1044-59.
13. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC and Vyavahare NR: **Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases**. *Circulation* 2004, **110**:3480-7.
14. Simionescu A, Philips K and Vyavahare N: **Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells**. *Biochem Biophys Res Commun* 2005, **334**:524-32.
15. Takeshita S, Kikuno R, Tezuka K and Amann E: **Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I**. *Biochem J* 1993, **294 (Pt 1)**:271-8.
16. Kruzynska-Frejtag A, Wang J, Maeda M, Rogers R, Krug E, Hoffman S, Markwald RR and Conway SJ: **Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction**. *Dev Dyn* 2004, **229**:857-68.
17. Norris RA, Kern CB, Wessels A, Moralez EI, Markwald RR and Mjaatvedt CH: **Identification and detection of the periostin gene in cardiac development**. *Anat Rec A Discov Mol Cell Evol Biol* 2004, **281**:1227-33.
18. Yoshioka N, Fuji S, Shimakage M, Kodama K, Hakura A, Yutsudo M, Inoue H and Nojima H: **Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene**. *Exp Cell Res* 2002, **279**:91-9.
19. Norris RA, Borg TK, Butcher JT, Baudino TA, Banerjee I and Markwald RR: **Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin**. *Ann N Y Acad Sci* 2008, **1123**:30-40.
20. Lindner V, Wang Q, Conley BA, Friesel RE and Vary CP: **Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration**. *Arterioscler Thromb Vasc Biol* 2005, **25**:77-83.
21. Livak KJ and Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method**. *Methods* 2001, **25**:402-8.
22. Norris RA, Damon B, Mironov V, Kasyanov V, Ramamurthi A, Moreno-Rodriguez R, Trusk T, Potts JD, Goodwin RL, Davis J, Hoffman S, Wen X, Sugi Y, Kern CB, Mjaatvedt CH, Turner DK, Oka T, Conway SJ, Molkentin JD, Forgacs G and Markwald RR: **Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues**. *J Cell Biochem* 2007, **101**:695-711.
23. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L and Trono D: **Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery**. *J Virol* 1998, **72**:9873-80.
24. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF and Kudo A: **Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta**. *J Bone Miner Res* 1999, **14**:1239-49.
25. Allen MR, Hock JM and Burr DB: **Periosteum: biology, regulation, and response to osteoporosis therapies**. *Bone* 2004, **35**:1003-12.
26. Bonewald LF: **Establishment and characterization of an osteocyte-like cell line, MLO-Y4**. *J Bone Miner Metab* 1999, **17**:61-5.
27. Kato Y, Boskey A, Spevak L, Dallas M, Hori M and Bonewald LF: **Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture**. *J Bone Miner Res* 2001, **16**:1622-33.
28. Hinek A, Wrenn DS, Mecham RP and Barondes SH: **The elastin receptor: a galactoside-binding protein**. *Science* 1988, **239**:1539-41.
29. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF and Rich JN: **SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility**. *Mol Cancer Ther* 2004, **3**:737-45.
30. Xiao G, Jiang D, Ge C, Zhao Z, Lai Y, Boules H, Phimphilai M, Yang X, Karsenty G and Franceschi RT: **Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression**. *J Biol Chem* 2005, **280**:30689-96.
31. Sinha S, Eddington H and Kalra PA: **Vascular calcification: lessons from scientific models**. *J Ren Care* 2009, **35 Suppl 1**:51-6.
32. Boyan BD, Schwartz Z and Swain LD: **Matrix vesicles as a marker of endochondral ossification**. *Connect Tissue Res* 1990, **24**:67-75.
33. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL and Edmonds ME: **Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification**. *Circulation* 1999, **100**:2168-76.

34. Moss DW, Eaton RH, Smith JK and Whitby LG: **Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations**. *Biochem J* 1967, **102**:53-7.
35. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI and O'Neill WC: **Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin**. *J Am Soc Nephrol* 2004, **15**:1392-401.
36. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A and Karsenty G: **Increased bone formation in osteocalcin-deficient mice**. *Nature* 1996, **382**:448-52.
37. Zhu S, Barbe MF, Liu C, Hadjiargyrou M, Popoff SN, Rani S, Safadi FF and Litvin J: **Periostin-like-factor in osteogenesis**. *J Cell Physiol* 2009, **218**:584-92.